Titre : Galectine -3

Galectine -3 : Questions médicales fréquentes

Termes MeSH sélectionnés :

Retinal Detachment
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Galectine -3 : Questions médicales les plus fréquentes", "headline": "Galectine -3 : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Galectine -3 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-05-17", "dateModified": "2025-02-11", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Galectine -3" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Galectines", "url": "https://questionsmedicales.fr/mesh/D037161", "about": { "@type": "MedicalCondition", "name": "Galectines", "code": { "@type": "MedicalCode", "code": "D037161", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.503.307" } } }, "about": { "@type": "MedicalCondition", "name": "Galectine -3", "alternateName": "Galectin 3", "code": { "@type": "MedicalCode", "code": "D037502", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Çiğdem Yücel", "url": "https://questionsmedicales.fr/author/%C3%87i%C4%9Fdem%20Y%C3%BCcel", "affiliation": { "@type": "Organization", "name": "Department of Biochemistry, University of Health Science, Ankara City Hospital, Ankara, Turkey." } }, { "@type": "Person", "name": "Aybeniz Civan Kahve", "url": "https://questionsmedicales.fr/author/Aybeniz%20Civan%20Kahve", "affiliation": { "@type": "Organization", "name": "Gazi University Faculty of Medicine, Department of Psychiatry, Ankara, Turkey." } }, { "@type": "Person", "name": "Işık Batuhan Çakmak", "url": "https://questionsmedicales.fr/author/I%C5%9F%C4%B1k%20Batuhan%20%C3%87akmak", "affiliation": { "@type": "Organization", "name": "Sungurlu State Hospital, Department of Psychiatry, Corum, Turkey." } }, { "@type": "Person", "name": "Erol Göka", "url": "https://questionsmedicales.fr/author/Erol%20G%C3%B6ka", "affiliation": { "@type": "Organization", "name": "University of Health Sciences, Ankara City Hospital, Department of Psychiatry, Ankara, Turkey." } }, { "@type": "Person", "name": "Massiullah Shafaq-Zadah", "url": "https://questionsmedicales.fr/author/Massiullah%20Shafaq-Zadah", "affiliation": { "@type": "Organization", "name": "Institut Curie, PSL Research University, U1143 INSERM, UMR3666 CNRS, Cellular and Chemical Biology Unit, 75248Paris Cedex 05, France." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Meteorological factors and rhegmatogenous retinal detachment in metropolitan France.", "datePublished": "2024-08-14", "url": "https://questionsmedicales.fr/article/39143097", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41598-024-69591-1" } }, { "@type": "ScholarlyArticle", "name": "Outcomes of chronic macula-off retinal detachment repair.", "datePublished": "2022-10-27", "url": "https://questionsmedicales.fr/article/36289075", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s00417-022-05876-3" } }, { "@type": "ScholarlyArticle", "name": "Lincoff's Rule Is Not Followed in Pediatric Rhegmatogenous Retinal Detachments.", "datePublished": "2022-06-06", "url": "https://questionsmedicales.fr/article/35666626", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1080/08820538.2022.2085514" } }, { "@type": "ScholarlyArticle", "name": "Retinal Detachments Associated With Topical Pilocarpine Use for Presbyopia.", "datePublished": "2022-05-21", "url": "https://questionsmedicales.fr/article/35609677", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.ajo.2022.05.011" } }, { "@type": "ScholarlyArticle", "name": "A retinal detachment based strabismus detection through FEDCNN.", "datePublished": "2024-10-06", "url": "https://questionsmedicales.fr/article/39370435", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41598-024-72919-6" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides aminés, peptides et protéines", "item": "https://questionsmedicales.fr/mesh/D000602" }, { "@type": "ListItem", "position": 3, "name": "Protéines", "item": "https://questionsmedicales.fr/mesh/D011506" }, { "@type": "ListItem", "position": 4, "name": "Lectines", "item": "https://questionsmedicales.fr/mesh/D037102" }, { "@type": "ListItem", "position": 5, "name": "Galectines", "item": "https://questionsmedicales.fr/mesh/D037161" }, { "@type": "ListItem", "position": 6, "name": "Galectine -3", "item": "https://questionsmedicales.fr/mesh/D037502" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Galectine -3 - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Galectine -3", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-06", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Galectine -3", "description": "Comment mesurer le taux de galectine-3 ?\nQuels tests sont utilisés pour le diagnostic ?\nLa galectine-3 est-elle un biomarqueur ?\nQuels médecins évaluent la galectine-3 ?\nPeut-on détecter la galectine-3 dans l'urine ?", "url": "https://questionsmedicales.fr/mesh/D037502?mesh_terms=Retinal+Detachment&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Galectine -3", "description": "Quels symptômes sont liés à la galectine-3 ?\nLa galectine-3 cause-t-elle des douleurs ?\nY a-t-il des symptômes cardiaques associés ?\nLa galectine-3 est-elle liée à la fatigue ?\nQuels signes cliniques sont observés ?", "url": "https://questionsmedicales.fr/mesh/D037502?mesh_terms=Retinal+Detachment&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Galectine -3", "description": "Comment prévenir l'augmentation de la galectine-3 ?\nL'exercice physique influence-t-il la galectine-3 ?\nY a-t-il des aliments à éviter ?\nLe stress affecte-t-il la galectine-3 ?\nDes suppléments peuvent-ils aider à la prévention ?", "url": "https://questionsmedicales.fr/mesh/D037502?mesh_terms=Retinal+Detachment&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Galectine -3", "description": "Quels traitements ciblent la galectine-3 ?\nLa galectine-3 peut-elle être traitée par des médicaments ?\nY a-t-il des traitements naturels pour la galectine-3 ?\nLes traitements varient-ils selon la maladie ?\nLa thérapie génique peut-elle cibler la galectine-3 ?", "url": "https://questionsmedicales.fr/mesh/D037502?mesh_terms=Retinal+Detachment&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Galectine -3", "description": "Quelles complications sont liées à la galectine-3 ?\nLa galectine-3 aggrave-t-elle les maladies ?\nY a-t-il des risques de cancer associés ?\nLa galectine-3 influence-t-elle la fibrose ?\nDes complications neurologiques sont-elles possibles ?", "url": "https://questionsmedicales.fr/mesh/D037502?mesh_terms=Retinal+Detachment&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Galectine -3", "description": "Quels facteurs augmentent la galectine-3 ?\nLe tabagisme influence-t-il la galectine-3 ?\nL'âge est-il un facteur de risque ?\nLe stress chronique est-il un facteur de risque ?\nY a-t-il un lien avec les maladies auto-immunes ?", "url": "https://questionsmedicales.fr/mesh/D037502?mesh_terms=Retinal+Detachment&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment mesurer le taux de galectine-3 ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le taux de galectine-3 se mesure par un test sanguin spécifique." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour le diagnostic ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests sanguins et des examens d'imagerie peuvent être utilisés." } }, { "@type": "Question", "name": "La galectine-3 est-elle un biomarqueur ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle est considérée comme un biomarqueur pour certaines maladies." } }, { "@type": "Question", "name": "Quels médecins évaluent la galectine-3 ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Les cardiologues et oncologues évaluent souvent la galectine-3." } }, { "@type": "Question", "name": "Peut-on détecter la galectine-3 dans l'urine ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "La galectine-3 est principalement mesurée dans le sang, pas dans l'urine." } }, { "@type": "Question", "name": "Quels symptômes sont liés à la galectine-3 ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Elle est associée à des symptômes d'inflammation et de fibrose." } }, { "@type": "Question", "name": "La galectine-3 cause-t-elle des douleurs ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Elle peut contribuer à des douleurs liées à des maladies inflammatoires." } }, { "@type": "Question", "name": "Y a-t-il des symptômes cardiaques associés ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des symptômes comme l'essoufflement peuvent être présents." } }, { "@type": "Question", "name": "La galectine-3 est-elle liée à la fatigue ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Elle peut être associée à la fatigue dans des conditions inflammatoires." } }, { "@type": "Question", "name": "Quels signes cliniques sont observés ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Des signes comme l'œdème et la dyspnée peuvent être observés." } }, { "@type": "Question", "name": "Comment prévenir l'augmentation de la galectine-3 ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Un mode de vie sain, incluant une alimentation équilibrée, peut aider." } }, { "@type": "Question", "name": "L'exercice physique influence-t-il la galectine-3 ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exercice régulier peut réduire les niveaux de galectine-3." } }, { "@type": "Question", "name": "Y a-t-il des aliments à éviter ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Éviter les aliments transformés et riches en sucres peut être bénéfique." } }, { "@type": "Question", "name": "Le stress affecte-t-il la galectine-3 ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress chronique peut augmenter les niveaux de galectine-3." } }, { "@type": "Question", "name": "Des suppléments peuvent-ils aider à la prévention ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Certains suppléments, comme les oméga-3, peuvent être bénéfiques." } }, { "@type": "Question", "name": "Quels traitements ciblent la galectine-3 ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Des inhibiteurs de galectine-3 sont en développement pour diverses maladies." } }, { "@type": "Question", "name": "La galectine-3 peut-elle être traitée par des médicaments ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains médicaments visent à réduire son activité dans le corps." } }, { "@type": "Question", "name": "Y a-t-il des traitements naturels pour la galectine-3 ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Des approches diététiques et des suppléments peuvent aider à la réguler." } }, { "@type": "Question", "name": "Les traitements varient-ils selon la maladie ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les traitements dépendent de la maladie associée à la galectine-3." } }, { "@type": "Question", "name": "La thérapie génique peut-elle cibler la galectine-3 ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Des recherches explorent la thérapie génique pour moduler son expression." } }, { "@type": "Question", "name": "Quelles complications sont liées à la galectine-3 ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Elle est liée à des complications cardiovasculaires et pulmonaires." } }, { "@type": "Question", "name": "La galectine-3 aggrave-t-elle les maladies ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut aggraver des maladies comme l'insuffisance cardiaque." } }, { "@type": "Question", "name": "Y a-t-il des risques de cancer associés ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Des niveaux élevés de galectine-3 sont associés à un risque accru de cancer." } }, { "@type": "Question", "name": "La galectine-3 influence-t-elle la fibrose ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle joue un rôle clé dans le développement de la fibrose tissulaire." } }, { "@type": "Question", "name": "Des complications neurologiques sont-elles possibles ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Des études suggèrent un lien entre galectine-3 et maladies neurodégénératives." } }, { "@type": "Question", "name": "Quels facteurs augmentent la galectine-3 ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "L'obésité, le diabète et l'inflammation chronique augmentent la galectine-3." } }, { "@type": "Question", "name": "Le tabagisme influence-t-il la galectine-3 ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le tabagisme est un facteur de risque pour des niveaux élevés." } }, { "@type": "Question", "name": "L'âge est-il un facteur de risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les niveaux de galectine-3 augmentent souvent avec l'âge." } }, { "@type": "Question", "name": "Le stress chronique est-il un facteur de risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress chronique peut contribuer à des niveaux élevés de galectine-3." } }, { "@type": "Question", "name": "Y a-t-il un lien avec les maladies auto-immunes ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les maladies auto-immunes peuvent augmenter les niveaux de galectine-3." } } ] } ] }

Sources (6595 au total)

Outcomes of chronic macula-off retinal detachment repair.

There have been disparate outcomes in the few studies that have looked at anatomic success and visual acuity (VA) in chronic retinal rhegmatogenous detachment (RRD) repair. Chronic retinal detachments... After obtaining Institutional Review Board (IRB) approval, patients who had undergone surgical intervention for all diagnosis codes of RD were identified in the Denver Health Medical Center database. ... The average patient age was 53.8 years. The length of RRD duration ranged from 30 to 365 days (mean 136.7 days). Twenty-six (70.3% patients had proliferative vitreoretinopathy (PVR) grade C or greater... Chronic macula-off RD with a PVD should be identified as it is associated with much lower rates of initial re-attachment. Socioeconomic factors likely are the driving factor for patients with PVD-type...

Lincoff's Rule Is Not Followed in Pediatric Rhegmatogenous Retinal Detachments.

To validate Lincoff's rules (LRs) in cases of rhegmatogenous retinal detachment (RRD) in the pediatric age group and to identify factors in cases LR was not followed.... This was a retrospective study where 98 pediatric patients with RRD were identified through surgery records. Forty case sheets with complete record of ocular examination and surgical findings were ana... The median age of the study participants was 11 years ranging from 5 to 18 years. There were 35 (88%) boys and 5 (12%) girls in the study. Myopia was noted in 13 (33%) eyes and in 21 (53%) eyes, there... LRs fail to accurately identify the exact location of the retinal break due to its posterior location and absence of posterior vitreous detachment in most cases with pediatric RRDs....

Retinal Detachments Associated With Topical Pilocarpine Use for Presbyopia.

To present a case series of retinal detachments associated with the use of pilocarpine for presbyopia.... Multicenter case series of 3 eyes from 2 patients.... Patient 1, a 47-year-old man, presented with flashes and floaters in both eyes. The patient had started pilocarpine 1.25% drops 1 month prior for presbyopia in both eyes. He noted the onset of flashes... Pilocarpine and other miotics have long been suspected to be associated with an increased risk of retinal detachment. Prior to prescribing pilocarpine for presbyopia, physicians should inform patients...

Neovascular Glaucoma Associated with Chronic Rhegmatogenous Retinal Detachment.

To demonstrate the clinical features and natural course of chronic retinal detachment-associated neovascular glaucoma.... Ten patients, diagnosed with chronic retinal detachment-associated neovascular glaucoma during 2007-2016 were retrospectively investigated. Besides chronic retinal detachment, no patients had any neov... The mean age of patients was 57.5 years (range, 22-78 years). Complete retinal reattachment was achieved in three eyes, while partial or total chronic retinal detachment persisted in seven eyes. Wide-... In eyes with a chronic retinal detachment history, iris neovascularization and neovascular glaucoma can develop due to retinal capillary obstruction and chronic retinal ischemia, even after achieving ...

Pneumatic Retinopexy for Rhegmatogenous Retinal Detachment in Elderly Patients.

To assess clinical outcomes in elderly patients aged ≥ 75 years who underwent pneumatic retinopexy (PnR) for primary rhegmatogenous retinal detachment (RRD).... Retrospective cohort study.... Patients aged ≥ 75 years with primary RRD undergoing PnR.... This study evaluates clinical outcomes among eligible patients who presented from October 1, 2010, to December 31, 2022, with a minimum of 3 months' follow-up. There were no limitations with respect t... Pneumatic retinopexy primary anatomic reattachment rate and postoperative best corrected visual acuity (BCVA) at 3 months.... Eighty patients with a mean age of 80.6 ± 4.6 years were included in this study; 35% (28/80) were phakic and 34% (27/80) presented with a fovea-on RRD. The mean number of breaks in the detached retina... Elderly patients treated with PnR for primary RRD had relatively comparable primary anatomic reattachment rates with other surgical techniques such as pars plana vitrectomy and scleral buckle. Pneumat... The authors have no proprietary or commercial interest in any materials discussed in this article....

Retinal Detachment Prophylaxis for Patients With Stickler Syndrome: A Survey of Pediatric Retinal Specialist Treatment Preferences.

Stickler syndrome is the most common inherited cause of pediatric rhegmatogenous retinal detachment. The purpose of this study was to survey pediatric retinal surgeon preferences for prophylactic trea... A voluntary, anonymous 27-question survey was developed by RedCap and distributed to the Association of Pediatric Retinal Surgeons. The survey was distributed on March 17, 2021. Results were tabulated... Thirty-four (76% response rate) respondents completed the survey. Twenty-six (76%) reported primarily using prophylactic laser retinopexy, four (12%) preferred use of cryotherapy, and 12% reported usi... The majority of the United States. and international pediatric retinal surgeons use laser retinopexy as the primary method of prophylactic treatment. These results may serve as a benchmark for retinal...